Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Portfolio Pulse from
Vistagen Therapeutics, Inc. is advancing its pherine drug candidate, fasedienol, with ongoing studies for Social Anxiety Disorder and a new proof-of-concept for cancer cachexia. The cancer cachexia market is projected to grow significantly by 2032.
February 14, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics is progressing with its pherine drug candidate, fasedienol, for Social Anxiety Disorder and cancer cachexia. The latter market is expected to grow significantly, potentially benefiting Vistagen.
Vistagen's ongoing studies and new proof-of-concept for cancer cachexia indicate potential future revenue streams. The significant projected growth of the cancer cachexia market enhances the positive outlook for Vistagen's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100